Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Psychotropic Drugs and Opioids on Ventilation
NCT04310579Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of quetiapine (extended-release tablet, brand name: Bipresso) and paroxetine in schizophrenia, bipolar disorder (BD), major depressive disorder (MDD) and 1 more (3 arms), sponsored by Food and Drug Administration. Primary endpoint: Minute Ventilation at the 55 mm Hg End Tidal Carbon Dioxide Point at Day 5. Started Jun 2020; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)paroxetine
03
Conditions
schizophreniabipolar disorder (BD)major depressive disorder (MDD)anxiety disorders
Beyond the preview
Go deeper on NCT04310579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310579.